Concepedia

Author

Marianne Noone

National Cancer Institute

Also Known As

M H Noone, M Noone, M. Noone, Marianne Noone

24

Publications

1.3K

Citations

18

H-Index

37

Concepts

All Affiliations

National Cancer InstituteNational Institutes of HealthNational Institutes of Health Clinical CenterNational Eye Institute
MN

About

Marianne Noone is an author at National Cancer Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

498

2

Cell Biology

3

3

365

3

Arts

1

1

24

4

Health Sciences

1

1

29

5

Public Health

1

1

24

Marianne Noone

×

19

Publications

1.3K

Citations

17

H-Index

YearCitations

Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer

J. Zujewski, Ivan D. Horak, C.J. Bol,

Journal of Clinical Oncology

2000

265

Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.

Lalage M. Wakefield, John J. Letterio, T Chen,

PubMed

1995

159

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.

K H Cowan, Jeffrey A. Moscow, Hui Huang,

PubMed

1999

125

Retroviral Mediated Transfer of the Human Multidrug Resistance Gene (MDR-1) into Hematopoietic Stem Cells During Autologous Transplantation after Intensive Chemotherapy for Metastatic Breast Cancer. National Institutes of Health, Bethesda, Maryland

Joyce O’Shaughnessy, Kenneth H. Cowan, Arthur W. Nienhuis,

Human Gene Therapy

1994

81

Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer.

Stacey L. Berg, Anthony W. Tolcher, Joyce O’Shaughnessy,

Journal of Clinical Oncology

1995

74

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.

Anthony W. Tolcher, Kenneth H. Cowan, D. Solomon,

Journal of Clinical Oncology

1996

73

Pilot Trial of the Safety, Tolerability, and Retinoid Levels of N-(4-hydroxyphenyl) Retinamide in Combination With Tamoxifen in Patients at High Risk for Developing Invasive Breast Cancer

Barbara A. Conley, Joyce O’Shaughnessy, Sheila A. Prindiville,

Journal of Clinical Oncology

2000

70

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.

Jason S. Fisherman, K H Cowan, Marianne Noone,

Journal of Clinical Oncology

1996

68

A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.

Elise C. Kohn, E Reed, Gisele Sarosy,

PubMed

2001

53

Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations

Julia Lawrence, Peter C. Adamson, Rafael C. Caruso,

Journal of Clinical Oncology

2001

50

Page 1